People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Other Technology, Biotech / Pharma, Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Olea Networks, Inc. | — | Other Technology | Series B | $50.5M | $695.1M | 2020 |
| Swift Biosciences, Inc. | — | Biotech / Pharma | Series A | $31.5M | $134.0M | 2012 |
| GlycosBio Inc. | — | Biotechnology | Series A | $12.3M | $6.9M | 2009 |
| Sinopsys Surgical, Inc. | — | Biotechnology | Series A | $10.2M | $298.5M | 2012 |
| Marval Biosciences Inc | — | Biotechnology | Seed | $6.5M | $111.0M | 2011 |
| Clean Chemistry, Inc. | — | Biotechnology | Seed | $2.9M | $22.2M | 2014 |
| DX Biosciences, Inc. | — | Other | Pre-Seed | $829K | $12.2M | 2010 |
| AskY Therapeutics, Inc. | — | Biotechnology | Pre-Seed | $740K | $2.3M | 2022 |
Dan Watkins at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dan Watkins on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Frank Foster | 2 | 12 |
| Russell Lebovitz | 2 | 3 |
| Robert Langer | 1 | 36 |
| Mark Lewis | 1 | 15 |
| Jack Ball | 1 | 10 |
| Steve Jurvetson | 1 | 10 |
| John Donovan | 1 | 8 |
| Paul Campbell | 1 | 6 |
| Mark Lupa | 1 | 5 |
| David Pearce | 1 | 5 |
| Linda Tufts | 1 | 5 |
| David Settle | 1 | 5 |
| Dan Kidle | 1 | 4 |
| Samir Mitragotri | 1 | 4 |
| Ken Kieley | 1 | 3 |
| Nathan Wood | 1 | 3 |
| Robert Di Scipio | 1 | 3 |
| Jimmy Treybig | 1 | 3 |
| Walter Young | 1 | 3 |
| John Westwick | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.